장기 산소 요법에서 고유량 요법의 효과 (HILOT)
장기 산소 요법(HILOT)에서 고유량 요법의 효과: 다기관, 레지스트리 기반, 무작위 임상 시험
This is a registry-based, randomized, controlled clinical trial of the effect of added high-flow oxygen therapy (using the device Lumis HFT) during one year in people with long-term oxygen therapy (LTOT) for chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD).
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
This is a registry-based, randomized, controlled clinical trial of patients with LTOT for COPD or ILD recruited using the Swedish National Registry for Respiratory Failure (Swedevox) in collaboration with a research network within the Swedish Respiratory Society. The trial evaluates the effect of added high-flow oxygen therapy nighttime to the regular low-flow oxygen therapy compared with regular low-flow oxygen therapy alone up to one year.
The purpose of this project is to improve evidence-based treatment of people with chronic respiratory failure, currently about 2000 patients annually in Sweden, who have high risk of adverse events and mortality.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 해당 없음
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Magnus Ekström, MD, PhD
- 전화번호: +46 0455731000
- 이메일: magnus.ekstrom@med.lu.se
연구 장소
-
-
-
Örebro, 스웨덴, 70185
- 모병
- Department of Heart, Lung and Clinical Physiology, Örebro University Hospital
-
연락하다:
- Josefin Sundh, MD, PhD
-
-
Blekinge County
-
Karlskrona, Blekinge County, 스웨덴, 37185
- 모병
- Research Unit, Blekinge University of Technology
-
연락하다:
- Magnus Ekström, MD, PhD
- 이메일: magnus.ekstrom@med.lu.se
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Age 40 years or older
- Ongoing LTOT: prescribed for at least 15 hours per day; and since at least 28 days as registered in Swedevox
- COPD or ILD as main underlying reason for LTOT
- Oxygen concentrator as stationary oxygen source in the home including night-time
- Body mass index (BMI) < 35 kg/m2
Exclusion Criteria:
- Current or previous treatment with home HFOT
- Current treatment with home mechanical ventilation
- Current treatment with home CPAP
- Hospitalized during the last 2 weeks
- Current smoking or contact with flames
- Self-reported average use of the LTOT < 15h per day (24 hours)
- PaCO2 (breathing air at rest) > 8 kPa
- Strong clinical suspicion of obstructive sleep apnea (OSA) or obesity-related hypoventilation syndrome (OHS) (as judged by the responsible staff)
- Inability to participate in the study procedures (as judged by the staff)
- Not eligible for continuing LTOT due to other reason (as judged by the staff)
- Expected survival less than 3 months (as judged by the staff)
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: High-flow oxygen therapy
Intervention arm |
Added high-flow oxygen therapy using the device Lumis HFT during nighttime and at the patient's discretion daytime, with the usual care (low-flow oxygen therapy) the rest of the time. |
|
활성 비교기: Low-flow oxygen therapy
Comparison arm |
Standard care with low-flow oxygen therapy in accordance with clinical routine. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Time to first hospitalization or death from all causes
기간: 1 year
|
Time to first hospitalization or death from all causes during 1 year after randomization in people with COPD (assessed using nationwide registry data) |
1 year
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Time to first all-cause hospitalization or all-cause death
기간: 1 year
|
Time to first all-cause hospitalization or all-cause death in people with ILD (assessed using nationwide registry data) |
1 year
|
|
Rate of hospitalizations or death from all causes
기간: 1 year
|
Rate of hospitalizations or death from all causes assessed using nationwide registry data |
1 year
|
|
Hospitalization rate from all causes
기간: 1 year
|
Hospitalization rate from all causes assessed using nationwide registry data |
1 year
|
|
Hospitalization rate from respiratory disease
기간: 1 year
|
Hospitalization rate from respiratory disease assessed using nationwide registry data |
1 year
|
|
Number of hospitalized days
기간: 1 year
|
Number of hospitalized days from all-causes, respiratory and cardiovascular disease using nationwide registry data |
1 year
|
|
Hospitalization rate from cardiovascular disease
기간: 1 year
|
Hospitalization rate from cardiovascular disease assessed using nationwide registry data |
1 year
|
|
Number of admissions to intensive care unit (ICU)
기간: 1 year
|
Number of admissions to ICU assessed using nationwide registry data |
1 year
|
|
Number of days in ICU
기간: 1 year
|
Number of days in ICU assessed using nationwide registry data |
1 year
|
|
Mortality rate from all causes
기간: 1 year
|
The mortality rate from all causes assessed using nationwide registry data |
1 year
|
|
Mortality rate from respiratory disease
기간: 1 year
|
The mortality rate from respiratory disease assessed using nationwide registry data |
1 year
|
|
Mortality rate from cardiovascular disease
기간: 1 year
|
The mortality rate from cardiovascular disease assessed using nationwide registry data |
1 year
|
|
Time to first exacerbation
기간: 1 year
|
Time to first exacerbation after randomisation, defined as time to first dispensed antibiotics and/or oral corticosteroids, ED-visit or hospitalization for exacerbation assessed using self-reported and registry data |
1 year
|
|
Number of exacerbations
기간: 1 year
|
Number of exacerbations of all severity assessed using self-reported and registry data |
1 year
|
|
Incidence of cardiovascular disease
기간: 1 year
|
Incidence of cardiovascular disease assessed using nationwide registry data |
1 year
|
|
Need for home mechanical ventilation
기간: 1 year
|
Need for starting home mechanical ventilation assessed using nationwide registry data |
1 year
|
|
Rate of withdrawal of long-term oxygen therapy
기간: 1 year
|
Rate of withdrawal of long-term oxygen therapy assessed using nationwide registry data |
1 year
|
|
Adverse events
기간: 3 and 12 months
|
Self-reported adverse events since study start assessed using a postal questionnaire. |
3 and 12 months
|
|
Primary care utilization
기간: 1 year
|
Self-reported number of primary care contacts since the start of the study assessed using a postal questionnaire. |
1 year
|
|
Health-related quality of life
기간: 3 and 12 months
|
Self-reported health-related quality of life assessed using the EuroQol Five Dimensions - Five Levels (EQ5D-5L) questionnaire. |
3 and 12 months
|
|
Health status
기간: 3 and 12 months
|
Self-reported health status assessed using the and the COPD Assessment Test (CAT) questionnaire. |
3 and 12 months
|
|
Breathlessness at exertion
기간: 3 and 12 months
|
Self-reported exertional breathlessness assessed using the Dyspnoea Exertion Scale (DES) questionnaire. |
3 and 12 months
|
|
Breathlessness
기간: 3 and 12 months
|
Self-reported breathlessness assessed using the Dyspnea-12 questionnaire. |
3 and 12 months
|
|
Sleep quality
기간: 3 and 12 months
|
Self-reported sleep quality assessed using the modified Basic Nordic Sleep Questionnaire. |
3 and 12 months
|
|
Physical activity
기간: 3 and 12 months
|
Self-reported level of physical activity assessed using the modified Grimby-Frändin questionnaire. |
3 and 12 months
|
|
Change in health status
기간: 3 and 12 months
|
Self-reported change in perceived health status assessed using the Global Impression of Change (GIC) scale. |
3 and 12 months
|
|
Nasal symptoms
기간: 3 and 12 months
|
Self-reported nasal symptoms assessed using the modified Björklund questionnaire. |
3 and 12 months
|
기타 결과 측정
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Patient preference for continuing the treatment
기간: 3 and 12 months
|
Patients' self-reported patient preference for continuing the treatment assessed using postal questionnaire. |
3 and 12 months
|
공동 작업자 및 조사자
협력자
협력자
수사관
수사관
- 수석 연구원: Magnus Ekström, MD, PhD, Skane University Hospital
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- HILOT
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
IPD cannot be shared due to restrictions in the current ethical approval. Pseudonymized IPD can be shared upon reasonable request and separate ethical approval.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .